본문 바로가기
KERD
논문KCI 등재

A non-replicating oncolytic vector as a novel therapeutic tool against cancer

Yasufumi Kaneda
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2010.12|BMB Reports|제43권 제12호|pp. 773-780

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

CancerApoptosisGene therapyAnti-tumor immunityHVJ
주제분류화학

초록

Cancers are still difficult targets despite recent advances in cancer therapy. Due to the heterogeneity of cancer, a single-treatment modality is insufficient for the complete elimination of cancer cells. Therapeutic strategies from various aspects are needed. Gene therapy has been expected to bring a breakthrough to cancer therapy, but it has not yet been successful. Gene therapy also should be combined with other treatments to enhance multiple therapeutic pathways. In this view, gene delivery vector itself should be equipped with intrinsic anti-cancer activities. HVJ (hemagglutinating virus of Japan; Sendai virus) envelope vector (HVJ-E) was developed to deliver therapeutic molecules. HVJ-E itself possessed anti-tumor activities such as the generation of anti-tumor immunities and the induction of cancer-selective apoptosis. In addition to the intrinsic anti-tumor activities, therapeutic molecules incorporated into HVJ-E enabled to achieve multi-modal therapeutic strategies in cancer treatment. Tumor-targeting HVJ-E was also developed. Thus, HVJ-E will be a novel promising tool for cancer treatment.

Abstract

Cancers are still difficult targets despite recent advances in cancer therapy. Due to the heterogeneity of cancer, a single-treatment modality is insufficient for the complete elimination of cancer cells. Therapeutic strategies from various aspects are needed. Gene therapy has been expected to bring a breakthrough to cancer therapy, but it has not yet been successful. Gene therapy also should be combined with other treatments to enhance multiple therapeutic pathways. In this view, gene delivery vector itself should be equipped with intrinsic anti-cancer activities. HVJ (hemagglutinating virus of Japan; Sendai virus) envelope vector (HVJ-E) was developed to deliver therapeutic molecules. HVJ-E itself possessed anti-tumor activities such as the generation of anti-tumor immunities and the induction of cancer-selective apoptosis. In addition to the intrinsic anti-tumor activities, therapeutic molecules incorporated into HVJ-E enabled to achieve multi-modal therapeutic strategies in cancer treatment. Tumor-targeting HVJ-E was also developed. Thus, HVJ-E will be a novel promising tool for cancer treatment.

참고문헌 (52)

  1. Moon, C., "Current status of gene therapy for lung cancer and head and neck cancer", Clin. Cancer Res., 9, pp.5055~5067 (2003)
  2. Fujiwara, T., "Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer", J. Clin. Oncol., 24, pp.1689~1699 (2006)
  3. O'Neill, D., "Exploiting dendritic cells for active immunotherapy of cancer and chronic infection", Methods Mol. Med., 109, pp.1~18 (2005)
  4. Kim, R., "Cancer immunosuppression and autoimmune disease: beyond immunosuppressive network for tumor immunity", Immunology, 119, pp.254~264 (2006)
  5. Dudley, M. E., "Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens", J. Clin. Oncol., 26, pp.5233~5239 (2008)
  6. Kirkwood, J. M., "Next generation of immunotherapy for melanoma", J. Clin. Oncol., 20, pp.3445~3455 (2008)
  7. Samuel, M., "Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma", Database Syst. Rev. Jan., 21(1), pp.CD001199~ (2009)
  8. Kelly, E., "History of oncolytic viruses: genesis to genetic engineering", Mol. Ther., 15, pp.651~659 (2007)
  9. Liu, T. C., "Gene therapy progress and prospects cancer: oncolytic viruses", Gene Ther., 15, pp.877~884 (2008)
  10. Kirn, D. H., "Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer", Nat. Rev. Cancer, 9, pp.64~71 (2009)
  11. Kaneda, Y., "HVJ (hemagglutinating virus of Japan) envelope vector as a versatile gene delivery system", Mol. Ther., 6, pp.219~226 (2002)
  12. Kaneda, Y., "Update on non-viral delivery methods for cancer therapy; possibilities of DDS with anti-cancer activities beyond delivery as a new therapeutic tool", Expert Opinion Drug Delivery, 9, pp.1079~1093 (2010)
  13. Okada, Y., "Sendai virus-induced cell fusion; in Methods in Enzymology volume 221", pp.18~41 (1993), Academic Press, Inc.
  14. Kaneda, Y., "Gene therapy using HVJ-liposomes; the best of both worlds", Mol. Med. Today, 5, pp.298~303 (1999)
  15. Kaneda, Y., "Applications on hemagglutinating virus of Japan in therapeutic delivery system", Expert Opinion Drug Delivery, 5, pp.221~233 (2008)
  16. Kaneda, Y., "Development of HVJ envelope vector and its application to gene therapy", Adv. Genet., 53PA, pp.307~332 (2005)
  17. Kurooka, M., "Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells", Cancer Res., 67, pp.227~236 (2007)
  18. Fujihara, A., "Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation", Cancer Immunol. Immunother., 57, pp.73~84 (2008)
  19. Pasare, C., "Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells", Science, 299, pp.1033~1036 (2003)
  20. Lal, G., "Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation", J. Immunol., 182, pp.259~273 (2009)
  21. Kato, H., "Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses", Nature, 441, pp.101~105 (2006)
  22. Seth, R. B., "Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3", Cell, 122, pp.669~682 (2005)
  23. Tang, E. D., "TRAF5 is a downstream target of MAVS in antiviral innate immune signaling", PLoS One, 5(2), pp.e9172~ (2010)
  24. Suzuki, H., "Sendai virus F glycoprotein induces IL-6 production in dendritic cells in a fusion-independent manner", FEBS Letter, 582, pp.1325~1329 (2008)
  25. Kawaguchi, Y., "Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle", Int. J. Cancer, 124, pp.2478~2487 (2009)
  26. Sadler, J., "Interferon-inducible antiviral effects", Nat. Rev. Immunology, 8, pp.559~568 (2008)
  27. Platanias, L. C., "Signaling pathways activated by interferons", Exp. Hematol., 11, pp.1583~1592 (1999)
  28. Tanaka, M., "Sterile alpha motif containing domain 9 (SAMD9) is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ-E) or type I interferon", Int. J. Cancer, 126, pp.1982~1991 (2010)
  29. Ito, M., "Rad51 siRNA delivered by HVJ envelope vector enhances the anticancer effect of cisplatin", J. Gene Med., 7, pp.1044~1052 (2005)
  30. Blangy, A., "Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo", Cell, 83, pp.1159~1169 (1995)
  31. Matsuda, M., "Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope", Gene Ther., 16, pp.1465~1476 (2009)
  32. Lefranc, F., "Granulocyte macrophage-colony stimulating factor gene transfer to induce a protective anti-tumoral immune response against the 9 L rat gliosarcoma model", Int. J. Oncol., 20, pp.1077~1085 (2002)
  33. Pan, D., "Adenovirus mediated transfer of p53, GM-CSF and B7-1 suppresses growth and enhances immunogenicity of glioma cells", Neurol. Res. (2009)
  34. Natsume, A., "Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse", Gene Ther., 6, pp.1626~1633 (1999)
  35. Meijer, D. H., "Controlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-beta", Cancer Gene Ther., 16, pp.664~671 (2009)
  36. Glick, R. P., "Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2", Neurosurgery, 45, pp.867~874 (1999)
  37. Iwadate, Y., "Recombinant Sendai virus vector induces complete remission of established brain tumors through efficient interleukin-2 gene transfer in vaccinated rats", Clin. Cancer Res., 11, pp.3821~3827 (2005)
  38. Liu, Y., "In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma", Cancer Gene Ther., 9, pp.9~15 (2002)
  39. Hellums, E. K., "Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model", Neuro. Oncol., 7, pp.213~224 (2005)
  40. Matsuda, M., "Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma" (2010), J. Neurooncol. In press
  41. Malek, T. R., "Tolerance, not immunity, crucially depends on IL-2", Nat. Rev. Immunol., 4, pp.665~674 (2004)
  42. Furtado, G. C., "Interleukin 2 signaling is required for CD4(+) regulatory T cell function", J. Exp. Med., 196, pp.851~857 (2002)
  43. Kawachi, M., "Development of tissue-targeting HVJ envelope vector for successful delivery of therapeutic gene to mouse skin", Hum. Gene Ther., 18, pp.881~894 (2007)
  44. Shimbo, T., "Development of a transferrin receptor-targeting HVJ-E vector", Biochem. Biophys. Res. Comm., 364, pp.423~428 (2007)
  45. Saga, K., "Functional modification of Sendai virus by siRNA", J. Biotechnol., 133, pp.386~394 (2008)
  46. Kircheis, R., "Transferrin receptortargeted gene delivery systems; in Polymeric Gene Delivery", pp.537~556 (2005), CRC Press LLC
  47. Sudimack, J., "Targeted drug delivery via the folate receptor", Adv. Drug Deliv. Rev., 41, pp.147~162 (2000)
  48. Morris, J. C., "Antibody-based therapy of leukaemia", Expert Rev. Mol. Med., 11, pp.e29~ (2009)
  49. Vallera, D. A, "Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy", Leuk. Res., 33, pp.1233~1242 (2009)
  50. van Waarde, A., "Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands" (2010), Curr. Pharm. Des. In press
  51. Chono, S., "An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor", J. Control Release, 131, pp.64~69 (2008)
  52. Clément, V., "Limits of CD133 as a marker of glioma self-renewing cells", Int. J. Cancer, 125, pp.244~248 (2009)

관련 논문AI추천

Oncolytic Viruses and Its Commercialization A mini review김홍균, 박영석, 이주원대한구강해부학회 · 대한구강해부학회지2016 · 제37권 제1호Sendai F/HN Viroplexes for Efficient Transfection of Leukemic T Cells강성재, 김근식, 김동은, 김민우, 김정석, 김홍성, 박용석, 유승현, 이연경, 정화연연세대학교의과대학 · Yonsei Medical Journal2013 · 제54권 제5호Naturally occurring reoviruses for human cancer therapy김만복생화학분자생물학회 · BMB Reports2015 · 제48권 제8호Split genome-based retroviral replicating vectors achieve efficient gene delivery and therapeutic effect in a human glioblastoma xenograft modelAyoung Song, Jiyoung Kim, Moonkyung Kang, Sang-Jin Lee, Se Hun Kang, Yeon-Soo Kim생화학분자생물학회 · BMB Reports2022 · 제55권 제12호The Suicide Gene Diphtheria Toxin A Based Therapy in Cancer Treatment정동기, Anh Nguyen.T.Q한국발생생물학회 · 발생과 생식2012 · 제16권 제3호Current advances in adenovirus nanocomplexes: more specificity and less immunogenicity강은아, 윤채옥생화학분자생물학회 · BMB Reports2010 · 제43권 제12호

이 간행물의 다른 논문 (10건)

Current advances in adenovirus nanocomplexes: more specificity and less immunogenicity윤채옥, 강은아pp. 781-788Cloning and characterization of a novel gene with alternative splicing in murine mesenchymal stem cell line C3H/10T1/2 by gene trap screeningZhongmin Zou, Tao Wang, Fan Jiang, Mingke Wang, Huiqin Sun, Jing Han, Feng Ye, Yongping Supp. 789-794Huntingtin-interacting protein 1-related is required for accurate congression and segregation of chromosomesSun Joo Parkpp. 795-800Soluble expression, purification and the role of C-terminal glycine residues in scorpion toxin BmK AGP-SYPU2Rong Zhang, Zhuo Yang, Yongshan Zhao, Yongbo Song, Chunfu Wu, Jinghai Zhang, Yong Cuipp. 801-806ZAS3 represses NFκB-dependent transcription by direct competition for DNA bindingLai-Chu Wu, 홍정우pp. 807-812
원문 보기